Sponsor or institution
Clinical trials and research at Chipscreen Biosciences, Ltd.
As of November 12, 2026, Find a Trial lists 7 clinical trials run by Chipscreen Biosciences, Ltd. that are recruiting, in China. By phase: Phase 1 (3), Phase 3 (2), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 7Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Chiglitazar added to SGLT-2 inhibitors for type 2 diabetes | — | Beijing, Beijing Municipality and 1 other locations | Recruiting | May 12, 2026 |
| CS32582 for moderate to severe plaque psoriasis | Phase 1/2 | Beijing, Beijing Municipality and 10 other locations | Recruiting | Aug 19, 2025 |
| Tucidinostat plus CHOP for newly diagnosed peripheral T‑cell lymphoma with T‑follicular helper phenotype | Phase 3 | Guangzhou, Guangdong | Recruiting | Apr 27, 2025 |
| Evaluating CS231295 for advanced solid tumors | Phase 1 | Beijing, Beijing Municipality and 1 other locations | Recruiting | Mar 30, 2025 |
| Combining Tucidinostat with Sintilimab and Bevacizumab for Colorectal Cancer | Phase 3 | Guangzhou, Guangdong | Recruiting | Jul 12, 2024 |
| Evaluating CS23546 for patients with advanced tumors | Phase 1 | Guangzhou | Recruiting | Feb 7, 2024 |
| Testing NWY001 in patients with advanced solid tumors | Phase 1 | Guangzhou, Guangdong | Recruiting | Aug 7, 2023 |
All recruiting trials (7)
-
Chiglitazar added to SGLT-2 inhibitors for type 2 diabetes
This real-world registry tests whether adding chiglitazar to ongoing SGLT-2 inhibitor therapy helps adults with type 2 diabetes improve blood sugar control and supports heart, kidney, and liver safety.
-
CS32582 for moderate to severe plaque psoriasis
This trial will test whether the oral medicine CS32582 helps adults with moderate to severe plaque psoriasis compared with a placebo.
-
Tucidinostat plus CHOP for newly diagnosed peripheral T‑cell lymphoma with T‑follicular helper phenotype
This trial tests whether adding tucidinostat to standard CHOP chemotherapy helps adults newly diagnosed with peripheral T‑cell lymphoma of the T‑follicular helper phenotype.
-
Evaluating CS231295 for advanced solid tumors
This study is testing a new drug called CS231295 to see if it is safe and effective for people with advanced solid tumors that haven't responded to other treatments.
-
Combining Tucidinostat with Sintilimab and Bevacizumab for Colorectal Cancer
This study is testing whether a new combination of three drugs can help people with a specific type of colorectal cancer live longer and feel better compared to a standard treatment.
-
Evaluating CS23546 for patients with advanced tumors
This study is testing a new treatment called CS23546 to see if it's safe and how well it works for people with advanced tumors.
-
Testing NWY001 in patients with advanced solid tumors
This study is testing a new treatment called NWY001 to see if it can help people with advanced solid tumors that haven't responded to other therapies.
Quick answers
How many clinical trials run by Chipscreen Biosciences, Ltd. are recruiting right now?
7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 3: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.